Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203

Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma

“…In the NJLCSG 1203 study, the primary endpoint was not met because of the low power of the study or the weak activity of thymoma. 25 It is recommended to conduct clinical trials with thymic carcinoma and thymoma with the inclusion of the extramural Corneal ulcer 0 (0) 1 (3.8) 0 (0) 0 (0) 0 (0)…”

“…Among them, only S‐1 showed clinical efficacy in a Japanese trial (NJLCSG 1203) comprising 40 patients with invasive thymoma and thymic carcinoma. In the NJLCSG 1203 study, the primary endpoint was not met because of the low power of the study or the weak activity of thymoma 25 . It is recommended to conduct clinical trials with thymic carcinoma and thymoma with the inclusion of the extramural review committee of independent pathologists to aid with the definitive diagnosis owing to the apparently different biological backgrounds.…”

S‐1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART‐1501

“…Theoretically, chemotherapy with concurrent radiotherapy seems to be ideal for locally advanced cases, as is the case in other malignancies; however, few prospective studies of treatments for thymic carcinoma have been performed. S‐1 was confirmed to be effective against thymic carcinoma in case reports and retrospective studies, in addition, a phase II study for previously‐treated thymic carcinoma has recently been reported . Overall response and disease control rates were 25% and 75%, respectively.…”

“…S-1 was confirmed to be effective against thymic carcinoma in case reports and retrospective studies, [5][6][7] in addition, a phase II study for previously-treated thymic carcinoma has recently been reported. 11 Overall response and disease control rates were 25% and 75%, respectively. S-1 plus cisplatin with concurrent radiotherapy has been reported to have a marked effect against thymic carcinoma.…”

Occurrence of Hematological Malignancy in Long-term Survivors With Advanced Thymic Cancer

“…Limited information is available on the therapeutic role of second-line or further chemotherapy. In Japan, amrubicin or S-1 is considered the best candidate for patients with relapsed TC as some case reports have demonstrated the effectiveness of amrubicin or S-1 treatment (2)(3)(4). However, these limited reports do not guarantee extended survival following successful sequential chemotherapy in patients with advanced or recurrent TC.…”